New heterodimeric nuclear receptors: Key metabolic regulators with relevance in the pathophysiology and therapy of dyslipidemias and diabetes mellitus;Nuevos receptores nucleares heterodiméricos reguladores metabólicos con impacto en fisiopatología y su proyección terapéutica en dislipidemias y diabetes mellitus

Revista Medica de Chile

Volumn 133, Issue 12, 2005, Pages 1483-1492

  Cortés, Víctor ^a   Quezada, Nicolás ^b   Rigotti, Attilio ^a   Maiz, Alberto ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Cytoplasmic and nuclear; Diabetes mellitus; Hyperlipidemia; Receptors

Indexed keywords

CELL RECEPTOR; RETINOIC ACID RECEPTOR;

CARBOHYDRATE METABOLISM; DIABETES MELLITUS; DYSLIPIDEMIA; GENETIC TRANSCRIPTION; GENETICS; HUMAN; LIPID METABOLISM; METABOLISM; PATHOPHYSIOLOGY; REVIEW;

CARBOHYDRATE METABOLISM; DIABETES MELLITUS; DYSLIPIDEMIAS; HUMANS; LIPID METABOLISM; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, RETINOIC ACID; TRANSCRIPTION, GENETIC;

EID: 32244445264     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. FRANCIS GA, FAYARD E, PICARD F, ALWERX J. Nuclear receptors and the control of metabolism. Annu Rev Physiol 2003; 65: 261-311.
2. CHAWLA A, REPA JJ, EVANS RM, MANGELSDORF DJ. Nuclear receptors and lipid physiology: opening the X-files. Science 2001; 294: 1866-70.
3. GRONEMEYER H, GUSTAFSSON JA LAUDET V. Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov 2004; 3: 950-64.
4. RANGWALA SM, LAZAR MA. Peroxisome proliferatoractivated receptor gamma in diabetes and metabolism. Trends Pharmacol Sci 2004; 25: 331-6.
5. STEFFENSEN KR, GUSTAFSSON JA Putative metabolic effects of the liver X receptor (LXR). Diabetes 2004; 53 Suppl 1: S36-42.
6. JOSEPH SB, CASTRILLO A, LAFFITTE BA, MANGELSDORF DJ, TONTONOZ P. Reciprocal regulation of inflam mation and lipid metabolism by liver X receptors. Nat Med 2003; 9: 213-9.
7. LEE CH, CHAWLA A, URBIZTONDO N, LIAO D, BOISVERT WA, EVANS RM ET AL Transcriptional repression of atherogenic inflammation: modulation by PPAR-delta. Science 2003; 302: 453-7.
8. TAN NS, MICHALIK L, DI-POI N, NG CY, MERMOD N, ROBERTS AB ET AL Essential role of Smad3 in the inhibition of inflammation-induced PPARbeta/ delta expression. Embo J 2004; 23: 4211-21.
9. TAN NE, MICHALIK L, DI-POI N, DESVERGNE B, WAHLI W. Critical roles of the nuclear receptor PPARbeta (peroxisome-proliferator-activated receptor beta) in skin wound healing. Biochem Soc Trans 2004; 32 (Pt 1): 97-102.
10. ROSEN ED, SPIEGELMAN BM PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 2001; 276: 37731-4.
11. DESVERGNE B, WAHLI W. Peroxisome proliferator activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20: 649-88.
12. TORRA IP, CHINETTI G, DUVAL C, FRUCHART JC, STAELS B. Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice. Curr Opin Lipidol 2001; 12: 245-54.
13. GEBEL T, ARAND M OESCH F. Induction of the peroxisome proliferator activated receptor by fenofibrate in rat liver. FEBS Lett 1992; 309: 37-40.
14. LEHMANN JM MOORE LB, SMITH-OLIVER TA. WILKISON WO, WILISON TM, KUEWER SA An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995; 270: 12953-6.
15. YKI-JARVINEN H. Thiazolidinediones. N Engl J Med 2004; 351: 1106-18.
16. UAUY R, MARTÍNEZ JI, ROJAS CV. [Molecular nutrition, role of the PPAR system in lipidic metabolism and its importance in obesity and diabetes mellitus]. Rev Méd Chile 2000; 128: 437-46.
17. WANG YX, ZHANG CL, YU RT, CHO HK, NELSON MC, BAYUGA-OCAMPO CR ET AL Regulation of muscle fiber type and running endurance by PPARdelta. PLoS Biol 2004; 2: e294.
18. PETERS JM LEE SS, LI W, WARD JM GAVRILOVA O, EVERETT C ET AL Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta). Mol Cell Biol 2000; 20: 5119-28.
19. BARAK Y, LIAO D, HE W, ONG ES, NELSON MC, OLEFSKY JM ET AL Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer. Proc Na tl Acad Sci USA 2002; 99: 303-8.
20. WANG YX, LEE CH, TIEP S, Yu RT, HAM J, KANG H ET AL. Peroxisome- proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 2003; 113: 159-70.
21. TANAKA T, YAMAMDTO J, IWASAKI S, ASABA H, HAMURA H, IKEDA Y ET AL Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Na tl Acad Sci USA 2003; 100: 15924-9.
22. OLIVER WR JR, SHENK JL, SNAITH MR, RUSSELL CS, PLUNKET KD, BODKIN NL ET AL A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport Proc Na tl Acad Sci USA 2001; 98: 5306-11.
23. VAN DER VEEN JH, KRUIT JK, HAVINGA R, BALLER JF, CHIMIN G, LESTAVEL S ET AL. Reduced cholesterol absoiption upon PPAR{delta} activation coincides with decreased intestinal expression of NPClLl. J Lipid Res 2005; 46: 526-34.
24. SHUREIQI I, JIANG W, ZUO X, Wu Y, STIMMEL JB, LEESNTZER LM ET AL The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid downregulates PPAR-delta to induce apoptosis in colorectal cancer cells. Proc Na tl Acad Sci USA 2003; 100: 9968-73.
25. GUPTA RA, WANG D, KATKURI S, WANG H, DEY SK, DUBOIS RN. Activation of nuclear hormone receptor peroxisome proliferator-activated receptordelta accelerates intestinal adenoma growth. Nat Med 2004; 10: 245-7.
26. JANOWSKL BA WILLY PJ, DEVI TR, FALCK JR, MANGELSDORF DJ. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 1996; 383: 728-31.
27. LEHMANN JM, KUEWER SA MOORE LB, SMITH-OLIVER TA, OLIVER BB, Su JL ET AL Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J Biol Chem 1997; 272: 3137-40.
28. MAKISHIMA M, OKAMOTO AY, REPA JJ, Tu H, LEARNED RM, LUK A ET AL Identification of a nuclear receptor for bile acids. Science 1999; 284: 1362-5.
29. WANG H, CHEN J, HOLLISTERK, SOWERS LC, FORMAN BM Endogenous bile acids are ligands for the nuclear receptor FXR/BAR Mol Cell 1999; 3: 543-53.
30. DIETSCHY JM, TURLEY SD, SPADY DK Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J Lipid Res 1993; 34: 1637-59.
31. REPA JJ, MANGELSDORF DJ. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu Rev Cell Dev Biol 2000; 16: 459-81.
32. PEET DJ, TURLEY SD, MA W, JANOWSKT BA, LOBACCARO JM, HAMMER RE ET AL Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 1998; 93: 693-704.
33. LU TT, REPA JJ, MANGELSDORF DJ. Orphan nuclear receptors as eLiXiRs and FiXeRs of sterol metabolism. J Biol Chem 2001; 276: 37735-8.
34. REPA JJ, TURLEY SD, LOBACCARO JA MEDINA J, LI L, LUSTLG K ET AL Regulation of absorption and ABCl-mediated efflux of cholesterol by RXR heterodimers. Science 2000; 289: 1524-9.
35. WANG N, LAN D, CHEN W, MATSUURA F, TALL AR ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteine Proc Na tl Acad Sci USA 2004; 101: 9774-9.
36. LAFFITTE BA, REPA JJ, JOSEPH SB, WILPITZ DC, KAST HR, MANGEISDORF DJ ET AL LXRs control lipidinducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc Na tl Acad Sci USA 2001; 98: 507-12.
37. SCHULTZ JR, TU H, LUK A, REPA JJ, MEDINA JC, LI L ET AL Role of LXRs in control of lipogenesis. Genes Dev 2000; 14: 2831-8.
38. Luo Y, TALL AR Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element J Clin Invest 2000; 105: 513-20.
39. REPA JJ, BERGE KE, POMAJZL C, RICHARDSON JA HOBBS H, MANGELSDORF DJ. Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J Biol Chem 2002; 277: 18793-800.
40. CAO G, LANG Y, BRODERICK CL, OLDHAM BA, BEYER TP, SCHMIDT RJ ET AL Antidiabetic action of a liver x receptor agonist mediated by inhibition of hepatic gluconeogenesis. J Biol Chem 2003; 278: 1131-6.
41. HORTON JD, SHIMOMURA I. Sterol regulatory element-binding proteins: activators of cholesterol and fatty acid biosynthesis. Cirr Opin Lipidol 1999; 10: 143-50.
42. REPA JJ, LIANG G, Ou J, BASHMAKOV Y, LOBACCARO JM, SHIMOMURA I ET AL Regulation of mouse sterol regulatory element-binding protein-1c gene (SRE-BP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev 2000; 14: 2819-30.
43. JOSEPH SB, MCKILLIGIN E, PEI L, WATSON MA COLLINS AR, LAFFITTE BA ET AL Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci USA 2002; 99: 7604-9.
44. SINAL CJ, TOHKIN M, MIYATA M, WARD JM, LAMBERT G, GONZALEZ FJ. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 2000; 102: 731-44.
45. URIZAR NL, LIVERMAN AB, DODDS DT, SILVA FV, ORDENTLICH P, YAN Y ET AL A natural product that lowers cholesterol as an antagonist ligand for FXR Science 2002; 296: 1703-6.
46. SATYAVATI GV, DWARAKANATH C, TRIPATHI SN. Experimental studies on the hypocholesterolemic effect of Commiphora mukul. Engl. (Guggul). Indian J Med Res 1969; 57: 1950-62.
47. AGARWAL RC, SINGH SP, SARAN RK, DAS SK, SINHA N, ASTHANA OP ET AL. Clinical trial of gugulipid - a new hypolipidemic agent of plant origin in primary hyperlipidemia. Indian J Med Res 1986; 84: 626-34.
48. NTYANAND S, SRIVASTAVA JS, ASTHANA OP. Clinical trials with gugulipid. A new hypolipidaemic agent. J Assoc Physicians India 1989; 37: 323-8.
49. SZAPARY PO, WOLFE ML, BLOEDON LT, CUCCHIARA AJ, DERMARDEROSIAN AH, CIRIGLIANO MD ET AL Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. J AMA 2003; 290: 765-72.
50. BURRIS TP, MONTROSE C, HOUCK KA, OSBORNE HE, BOCCHINFUSO WP, YADEN BC ET AL The hypolipidemic natural product guggulsterone is a promiscuous steroid receptor ligand. Mol Pharmacol 2005; 67: 948-54.
51. DURAN-SANDOVAL D, MAUTINO G, MARTIN G, PERCEVALLT F, BARBIER O, FRUCHART JC ET AL Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes 2004; 53: 890-8.
52. STAYROOK KR, BRAMLETT KS, SAVKUR RS, FICORILLI J, COOK T, CHRLSTE ME ET AL Regulation of carbohydrate metabolism by the famesoid X receptor. Endocrinology 2005; 146: 984-91.
53. WITTENBURG H, LYONS MA, LI R, CHURCHILL GA, CAREY MC, PAIGEN B. FXR and ABCG5/ABCG8 as determinants of cholesterol gallstone formation from quantitative trait locus mapping in mice. Gastroenterology 2003; 125: 868-81.
54. MOSCHETTA A, BOOKOUT AL, MANGELSDORF DJ. Prevention of cholesterol gallstone disease by FXR agonists in a mouse model. Nat Med 2004; 10: 1352-8.
55. SZANTO A, NARKAR V, SHEN Q, URAY IP, DAVIES PJ, NAGY L Retinoid X receptors: X-ploring their (patho) physiological functions. Cell Death Differ 2004; 11 Suppl 2: S126-43.
56. CLAUDEL T, LEIBOWITZ MD, FIEVET C ET AL Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. Proc Natl Acad Sci USA 2001; 98: 2610-5.
57. SHEN Q, CLINE GW, SHULMAN GI, LEIBOWITZ MD, DAVIES PJ. Effects of rexinoids on glucose transport and insulin-mediated signaling in skeletal muscles of diabetic (db/db) mice. J Biol Chem 2004; 279: 19721-31.